Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Vanderbilt Takes Investigational New Drug From Bench To Bedside


 
P. Jeffrey Conn, PhD

Patients with serious brain disorders such as Alzheimer's disease and schizophrenia could benefit from an investigational new drug (IND) that has received notification from the FDA that testing in humans may proceed after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

"This is the first instance I am aware of where an academic drug discovery group moved a molecule for treatment of chronic brain disorders all the way from early discovery to human trials without there being, at some point along the way, a pharmaceutical partner," said P. Jeffrey Conn, PhD, director, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). "And that really is crossing what people refer to all of the time as the 'Valley of Death,' where good research discoveries have a hard time moving into the real testing phase."

For Alzheimer's disease, the IND targets major pathologies of the disease and offers highly selective activation of a key receptor unlike the current standard of care, cholinesterase inhibitors. Vanderbilt researchers said the molecule might be broadly effective across a number of cognitive and neuropsychiatric disorders. In schizophrenia, current treatments address the positive symptoms of the disease, including hallucinations and delusions, but not the negative symptoms and cognitive disturbances of schizophrenia. "People who treat schizophrenia patients commonly agree that the negative symptoms and cognitive disturbances are the major factors that decrease the ability for these patients to integrate in society," Conn said. "And we have no treatments for those so our hope is that this molecule will be effective."

VCNDD Co-Director Craig W. Lindsley, PhD, director of Medicinal Chemistry and the William K. Warren, Jr. Chair in Medicine, said phase I testing will assess drug safety and tolerability in young healthy volunteers, a process that could take a year. If successful, the phase II and III studies would include patients with either Alzheimer's disease or schizophrenia and could take three-five years to complete.

 
Share:

Related Articles:


Recent Articles

Physicians Discuss Opioids, Scope of Practice and More During TMA Annual Meeting

State's Largest Professional Organization for Doctors Announces 2018-2019 Officers

Read More

Tristar Centennial Medical Center Announces Construction Of New Multi-Level Parking Garage

Tristar Centennial Medical Center is pleased to announce the construction of a new multi-level parking garage that will be located at the corner of 23rd Avenue and Patterson Street.

Read More

Healthcare Redesigned

Nature and sustainability are key in today's updated medical facilities.

Read More

McWhorter Society Luncheon Honors Healthcare Luminaries

The annual McWhorter Society Luncheon at Belmont University celebrated healthcare accomplishments by honoring Gov. Winfield C. Dunn and announcing the 2018 inductees into the Tennessee Health Care Hall of Fame.

Read More

Mazzetti+GBA Launches Tool for Healthcare Architects, Engineers

A new app unveiled in Nashville by Mazzetti+GBA supports project planning for healthcare architects, engineers

Read More

Making Medical Devices Lighter, Stronger, Safer

Locally company Can-Do National Tape is using their expertise in adhesives to make medical device and design lighter, stronger, safer.

Read More

NMGMA: 10 Minute Takeaway

You can't manage what you can't measure ... KraftCPA's Lucy Carter shares the basic principles of medical office accounting.

Read More

Insights from Inside the Beltway

As EBG celebrates their first anniversary in Nashville, senior strategists from the firm's D.C. office share insights from the nation's capital.

Read More

TennCare CMO Victor Wu

TennCare CMO launches programs aimed at improving health of Tennessee's Medicaid recipients.

Read More

Making the Grade

Men's Health Report card shows improvement in key markers.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: